Developer docs
API playgroundTry for free, no card

Search company profiles

Suneva Medical

Full company profile

uuid0000o7m

Namestring
Suneva Medical
Legal namestring
Suneva Medical, Inc.
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Suneva Medical, Inc. was a privately held medical aesthetics company founded in 2009 and headquartered in San Diego, California. It developed and commercialized a portfolio of FDA-cleared regenerative aesthetic products sold through a B2B distribution model targeting dermatologists, plastic surgeons, and cosmetic medicine practitioners. Its product portfolio centered on Bellafill, the first FDA-cleared 5-year biostimulatory dermal filler containing PMMA microspheres in bovine collagen gel for nasolabial fold and acne scar correction; Silhouette Instalift, the first absorbable suture FDA-cleared for cosmetic facial procedures providing minimally invasive lifting; and Amplifine PRP, a platelet-rich plasma platform for regenerative aesthetic treatments. The company also developed Viality, an enhanced-viability fat transfer system with a proprietary surfactant, and alloClae, a structural adipose tissue product for body aesthetics.

Suneva's business model relied on one-time product sales to licensed healthcare providers, with quote-based pricing and no disclosed subscription or recurring revenue component. Customer acquisition operated through a provider-locator model (the Sientra Surgeon Locator) and digital marketing channels including LinkedIn, Instagram, and a product website. The company funded growth through multiple venture and royalty-backed rounds between 2010 and 2020 — including financings from Essex Woodlands Healthcare Partners, Almirall, HealthCare Royalty Partners, and Polaris Partners — totaling approximately $175 million in disclosed capital.

In 2025, Suneva Medical was acquired by Tiger Aesthetics Medical, LLC, a strategic operating company in the regenerative aesthetics space. Following the transaction, Suneva's Bellafill, Silhouette Instalift, and Amplifine PRP product lines were integrated into Tiger Aesthetics' broader portfolio, which also includes Sientra silicone gel breast implants, Avéli cellulite treatment, alloClae, Viality, and breast tissue expanders (Dermaspan and AlloX2). Suneva continues to operate as a product brand within the Tiger Aesthetics commercial infrastructure.

Short descriptiontext

Suneva Medical was a San Diego-based medical aesthetics company that developed and sold FDA-cleared regenerative aesthetic products — including Bellafill, Silhouette Instalift, and Amplifine PRP — to dermatologists, plastic surgeons, and cosmetic practitioners. It was acquired by Tiger Aesthetics in 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical aesthetic devices, dermal fillers, regenerative aesthetics, cosmetic surgery products, plastic surgery supplies
Industry2 codes
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKACAE
Cosmetic Dermatology (Aesthetic Injectables)
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Aesthetic Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Aesthetic Products
TypeOne Time License
Description

Revenue generated from selling proprietary aesthetic medical devices and products to healthcare providers. The portfolio includes dermal fillers, absorbable threads, PRP systems, and breast tissue expanders sold through provider networks.

tiger-aesthetics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Marketing or Sales, Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Bellafill
Description

FDA cleared 5-year biostimulatory filler for aesthetic treatments

tiger-aesthetics.com
+2 more records
Core offering1 text field

Suneva Medical developed, manufactured, and commercialized FDA-cleared medical aesthetic products for dermatologists, plastic surgeons, and cosmetic surgery practices. Its core portfolio included Bellafill (the first FDA-cleared 5-year biostimulatory dermal filler), Silhouette Instalift (an absorbable suture thread lift), and the Amplifine PRP platform, with products sold exclusively through a B2B provider network distribution model.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Suneva Medical was a medical aesthetics company that developed and commercialized regenerative aesthetic products. Its portfolio included Bellafill (a biostimulatory filler), Silhouette Instalift (an absorbable thread lift device), and Amplifine PRP (a PRP platform). In 2025, Suneva Medical and its product portfolio were acquired by Tiger Aesthetics Medical, LLC. The products continue to be distributed and supported through Tiger Aesthetics' regenerative aesthetics portfolio.

Product and service1 record
1Bellafill
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Tiger Aesthetics Medical, LLC acquired Suneva Medical and its complete product portfolio including Bellafill, Silhouette Instalift, and Amplifine PRP products. This acquisition consolidated Suneva's regenerative aesthetics portfolio under Tiger Aesthetics' umbrella, combining complementary aesthetic device and filler offerings.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Owns the Juvederm filler franchise and Botox, the dominant aesthetics portfolio globally. Directly comparable as the leading aesthetics medical device and injectable competitor with substantially greater scale and broader provider relationships than Suneva.

TypeBroad incumbent
Description

Markets the Restylane and Sculptra filler portfolios alongside Dysport neuromodulators. A direct competitor in the dermal filler and biostimulator (Sculptra) categories where Suneva's Bellafill competes.

TypeBroad incumbent
Description

Sells Radiesse (calcium hydroxylapatite filler), Belotero, and Ultherapy in aesthetics. Directly comparable as a filler competitor with established provider relationships in dermatology and plastic surgery practices Suneva targets.

4Revance Therapeutics
TypeDirect peer
Description

Develops long-duration aesthetic injectables including Daxxify (long-lasting neuromodulator) and the RHA filler line. Directly comparable as a focused aesthetics injectable competitor pursuing differentiated longevity claims similar to Suneva's Bellafill positioning.

5Evolus
TypeDirect peer
Description

Specialty aesthetics company commercializing Jeuveau (prabotulinumtoxinA) and exploring broader injectable offerings. A comparable specialty aesthetics competitor targeting similar provider channels with a focused product strategy.

TypeDirect peer
Description

Aesthetic medicine company that developed Silhouette Instalift before Suneva's distribution and was later acquired by Huadong Medicine. Directly comparable as a developer of thread lift and regenerative aesthetics products with overlapping technology focus.

TypeDirect peer
Description

Aesthetic medical device company specializing in breast implants and body contouring products. Now a sister brand under Tiger Aesthetics alongside Suneva, making it a directly comparable aesthetics device peer with shared distribution channels.

8Croma-Pharma
TypeDirect peer
Description

European-based aesthetics company offering hyaluronic acid fillers (Princess line), PRP systems, and regenerative aesthetics products. Directly comparable as a multi-product aesthetics company competing in fillers and regenerative platforms similar to Suneva's portfolio.

TypeRegional player
Description

South Korean aesthetics company with botulinum toxin (Botulax/Letybo) and dermal filler products. Comparable as a competitor in aesthetic injectables with growing international expansion that overlaps with Suneva's provider markets.

TypeDirect peer
Description

Specialty manufacturer of the Revanesse line of hyaluronic acid dermal fillers. A directly comparable specialty filler competitor targeting the same provider network Suneva serves with a focused aesthetics product strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Suneva Medical

Medical Aesthetic Devicessunevamedical.com

Suneva Medical was a San Diego-based medical aesthetics company that developed and sold FDA-cleared regenerative aesthetic products — including Bellafill, Silhouette Instalift, and Amplifine PRP — to dermatologists, plastic surgeons, and cosmetic practitioners. It was acquired by Tiger Aesthetics in 2025.

What Suneva Medical does

Suneva Medical, Inc. was a privately held medical aesthetics company founded in 2009 and headquartered in San Diego, California. It developed and commercialized a portfolio of FDA-cleared regenerative aesthetic products sold through a B2B distribution model targeting dermatologists, plastic surgeons, and cosmetic medicine practitioners. Its product portfolio centered on Bellafill, the first FDA-cleared 5-year biostimulatory dermal filler containing PMMA microspheres in bovine collagen gel for nasolabial fold and acne scar correction; Silhouette Instalift, the first absorbable suture FDA-cleared for cosmetic facial procedures providing minimally invasive lifting; and Amplifine PRP, a platelet-rich plasma platform for regenerative aesthetic treatments. The company also developed Viality, an enhanced-viability fat transfer system with a proprietary surfactant, and alloClae, a structural adipose tissue product for body aesthetics.

Suneva's business model relied on one-time product sales to licensed healthcare providers, with quote-based pricing and no disclosed subscription or recurring revenue component. Customer acquisition operated through a provider-locator model (the Sientra Surgeon Locator) and digital marketing channels including LinkedIn, Instagram, and a product website. The company funded growth through multiple venture and royalty-backed rounds between 2010 and 2020 — including financings from Essex Woodlands Healthcare Partners, Almirall, HealthCare Royalty Partners, and Polaris Partners — totaling approximately $175 million in disclosed capital.

In 2025, Suneva Medical was acquired by Tiger Aesthetics Medical, LLC, a strategic operating company in the regenerative aesthetics space. Following the transaction, Suneva's Bellafill, Silhouette Instalift, and Amplifine PRP product lines were integrated into Tiger Aesthetics' broader portfolio, which also includes Sientra silicone gel breast implants, Avéli cellulite treatment, alloClae, Viality, and breast tissue expanders (Dermaspan and AlloX2). Suneva continues to operate as a product brand within the Tiger Aesthetics commercial infrastructure.

Suneva Medical firmographics

Firmographics
Name
Suneva Medical
Legal name
Suneva Medical, Inc.
Website
https://sunevamedical.com
Company type
Private
Founded year
2009
Operating status
Acquired
Headcount range
51–100 employees
Short description
Suneva Medical was a San Diego-based medical aesthetics company that developed and sold FDA-cleared regenerative aesthetic products — including Bellafill, Silhouette Instalift, and Amplifine PRP — to dermatologists, plastic surgeons, and cosmetic practitioners. It was acquired by Tiger Aesthetics in 2025.
Ownership category
akta.pro rank

Suneva Medical industry classification

Industry
Product category
Medical Aesthetic Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKACAE
Cosmetic Dermatology (Aesthetic Injectables)

Keywords

  • Medical aesthetic devices
  • Dermal fillers
  • Regenerative aesthetics
  • Cosmetic surgery products
  • Plastic surgery supplies

Where Suneva Medical is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Suneva Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Marketing or Sales, Technology or R&D, Personnel, Operations

Revenue model

  1. Medical Aesthetic Products: Revenue generated from selling proprietary aesthetic medical devices and products to healthcare providers. The portfolio includes dermal fillers, absorbable threads, PRP systems, and breast tissue expanders sold through provider networks.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Suneva Medical product offering

Product offering

Core offering

Suneva Medical developed, manufactured, and commercialized FDA-cleared medical aesthetic products for dermatologists, plastic surgeons, and cosmetic surgery practices. Its core portfolio included Bellafill (the first FDA-cleared 5-year biostimulatory dermal filler), Silhouette Instalift (an absorbable suture thread lift), and the Amplifine PRP platform, with products sold exclusively through a B2B provider network distribution model.

Product overview

Suneva Medical was a medical aesthetics company that developed and commercialized regenerative aesthetic products. Its portfolio included Bellafill (a biostimulatory filler), Silhouette Instalift (an absorbable thread lift device), and Amplifine PRP (a PRP platform). In 2025, Suneva Medical and its product portfolio were acquired by Tiger Aesthetics Medical, LLC. The products continue to be distributed and supported through Tiger Aesthetics' regenerative aesthetics portfolio.

Differentiator

Problem solved

Functional benefit

Brands

  • Bellafill: FDA cleared 5-year biostimulatory filler for aesthetic treatments
  • Silhouette Instalift
  • Amplifine PRP

Products and services

  • Bellafill

Companies that use Suneva Medical

Customer profile

Segments2 records

Ideal customer profiles1 record

Suneva Medical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Suneva Medical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Tiger Aesthetics Medical, LLCcoreStrategic or Co-development PartnerTiger Aesthetics Medical, LLC acquired Suneva Medical and its complete product portfolio including Bellafill, Silhouette Instalift, and Amplifine PRP products. This acquisition consolidated Suneva's regenerative aesthetics portfolio under Tiger Aesthetics' umbrella, combining complementary aesthetic device and filler offerings.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Suneva Medical competitors and assessment

Company assessment

Broad incumbents

  • AbbVie (Allergan Aesthetics): Owns the Juvederm filler franchise and Botox, the dominant aesthetics portfolio globally. Directly comparable as the leading aesthetics medical device and injectable competitor with substantially greater scale and broader provider relationships than Suneva.
  • Galderma: Markets the Restylane and Sculptra filler portfolios alongside Dysport neuromodulators. A direct competitor in the dermal filler and biostimulator (Sculptra) categories where Suneva's Bellafill competes.
  • Merz Aesthetics: Sells Radiesse (calcium hydroxylapatite filler), Belotero, and Ultherapy in aesthetics. Directly comparable as a filler competitor with established provider relationships in dermatology and plastic surgery practices Suneva targets.

Direct peers

  • Revance Therapeutics: Develops long-duration aesthetic injectables including Daxxify (long-lasting neuromodulator) and the RHA filler line. Directly comparable as a focused aesthetics injectable competitor pursuing differentiated longevity claims similar to Suneva's Bellafill positioning.
  • Evolus: Specialty aesthetics company commercializing Jeuveau (prabotulinumtoxinA) and exploring broader injectable offerings. A comparable specialty aesthetics competitor targeting similar provider channels with a focused product strategy.
  • Sinclair Pharma: Aesthetic medicine company that developed Silhouette Instalift before Suneva's distribution and was later acquired by Huadong Medicine. Directly comparable as a developer of thread lift and regenerative aesthetics products with overlapping technology focus.
  • Sientra: Aesthetic medical device company specializing in breast implants and body contouring products. Now a sister brand under Tiger Aesthetics alongside Suneva, making it a directly comparable aesthetics device peer with shared distribution channels.
  • Croma-Pharma: European-based aesthetics company offering hyaluronic acid fillers (Princess line), PRP systems, and regenerative aesthetics products. Directly comparable as a multi-product aesthetics company competing in fillers and regenerative platforms similar to Suneva's portfolio.
  • Prollenium Medical Technologies: Specialty manufacturer of the Revanesse line of hyaluronic acid dermal fillers. A directly comparable specialty filler competitor targeting the same provider network Suneva serves with a focused aesthetics product strategy.

Regional players

  • Hugel: South Korean aesthetics company with botulinum toxin (Botulax/Letybo) and dermal filler products. Comparable as a competitor in aesthetic injectables with growing international expansion that overlaps with Suneva's provider markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Suneva Medical social profiles

Digital presence

Suneva Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Suneva Medical leadership team

Management profile

Number of profiles

Profiles4 records

Suneva Medical funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Suneva Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Suneva Medical

What does Suneva Medical do?

Suneva Medical developed, manufactured, and commercialized FDA-cleared medical aesthetic products for dermatologists, plastic surgeons, and cosmetic surgery practices. Its core portfolio included Bellafill (the first FDA-cleared 5-year biostimulatory dermal filler), Silhouette Instalift (an absorbable suture thread lift), and the Amplifine PRP platform, with products sold exclusively through a B2B provider network distribution model.

Is Suneva Medical a public or private company?

Suneva Medical is a private company. It is classified as corporate owned and is currently acquired.

When was Suneva Medical founded?

Suneva Medical was founded in 2009. It employs 51 to 100 people.

Where is Suneva Medical based?

Suneva Medical is headquartered in San Diego, United States, in the North America region.

How does Suneva Medical make money?

One revenue line is on record: medical Aesthetic Products.

Who are Suneva Medical's main competitors?

Broad incumbents on record are AbbVie (Allergan Aesthetics), Galderma and Merz Aesthetics. Direct peers are Revance Therapeutics, Evolus, Sinclair Pharma, Sientra, Croma-Pharma and Prollenium Medical Technologies. Hugel is listed as a regional player.

Does Suneva Medical have an API?

No public API is recorded for Suneva Medical.

What industry is Suneva Medical in?

Suneva Medical's product category is Medical Aesthetic Devices. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of HLAKACAE, Cosmetic Dermatology (Aesthetic Injectables). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireViveon Health Acquisition Corp. Announces Termination of Merger Agreement with Suneva Medical, Inc.Viveon Health Acquisition Corp. unilaterally terminated its merger agreement with Suneva Medical, Inc. and will seek an alternative business combination. The SPAC, formed for healthcare targets in North America, will pursue prospective targets.GlobeNewswireVIVEON HEALTH ACQUISITION CORP. Announces Adjournment of Special Meeting in Connection with Vote to Consummate its Initial Business Combination with Suneva Medical, Inc. Until February 3, 2023.Viveon Health Acquisition Corp. adjourned its special meeting to vote on the merger with Suneva Medical until February 3, 2023. As of January 18, 2023, 1,798,631 shares were redeemed, leaving approximately $19.68 million in the trust account.GlobeNewswireVIVEON HEALTH ACQUISITION CORP. Announces that Redemption Reversals in Connection with Vote to Consummate its Initial Business Combination with Suneva Medical, Inc. Are Extended Until December 23, 202Viveon Health Acquisition Corp. extended the deadline for redeeming stockholders to reverse their redemption requests until December 23, 2022, in connection with its special meeting. The company received 4,628,145 redemption requests, with 404,729 shares remaining, and the meeting was adjourned to January 20, 2023.PR NewswireShareholder Alert - The M&A Class Action Firm Continues Investigating the Merger - ZEN, MANT, HMTV, CTT, HNGR, VHAQMonteverde & Associates PC, a securities class action law firm, announced it is investigating six proposed mergers on behalf of shareholders to assess whether the deal terms provide fair value: Zendesk's acquisition by Permira and Hellman & Friedman for $77.50 per share, ManTech International's acquisition by Carlyle Group for $96.00 per share, Hemisphere Media Group's acquisition by Gato Investments for $7.00 per share, CatchMark Timber Trust's acquisition by PotlatchDeltic for 0.23 shares per share, Hanger's acquisition by Patient Square Capital for $18.75 per share, and Viveon Health Acquisition Corp.'s merger with Suneva Medical.PR NewswireINVESTIGATION ALERT: Halper Sadeh LLP Investigates LJPC, ZEN, RFP, VHAQHalper Sadeh LLP, an investor rights law firm, announced investigations into four companies for potential violations of federal securities laws and breaches of fiduciary duties related to proposed transactions. The companies under scrutiny include La Jolla Pharmaceutical Company (sale to Innoviva at $6.23/share), Zendesk (sale to Permira and Hellman & Friedman at $77.50/share), Resolute Forest Products (sale to Domtar Corporation), and Viveon Health Acquisition Corp. (merger with Suneva Medical). The firm is offering free consultations to affected shareholders and may seek increased consideration or additional disclosures on their behalf.PR NewswireSuneva Medical Inc. Announces Multiple Regulatory Approvals in the U.S. and CanadaSuneva Medical, in partnership with Bimini Health Tech, received approval from Canada's Medical Devices Directorate to market the Dermapose® all-in-one fat sizing syringe in Canada and obtained U.S. FDA 510(k) clearance for a larger volume 30 mL Amplifine PRP gel tube. These dual regulatory approvals expand Suneva's regenerative aesthetic product offerings across the largest North American market. The company is separately pursuing a merger with Viveon Health Acquisition Corp. (NYSE American: VHAQ), a special purpose acquisition company, with completion expected to result in trading under the symbol RNEW.PR NewswireAnti-ageing Cosmetics Market Size to Reach USD 76.91 Billion in 2030, Increasing preference for non-toxic cosmetics and rising trend of looking younger is driving market revenue growth - Reports and DThe global anti-ageing cosmetics market is projected to reach USD 76.91 billion by 2030, growing at a 5.7% CAGR, driven by rising consumer demand for anti-ageing remedies and improving lifestyle standards globally. In January 2022, Suneva Medical Inc. merged with Viveon Health Acquisition Corp. to capitalize on growth in beauty and anti-ageing solutions, including hair restoration products. Key barriers to market expansion include the high cost of anti-ageing products and concerns over counterfeit cosmetics containing toxic substances.PR NewswireViveon Health Acquisition Corp. Announces Board and Stockholder Approval to Extend Period to Consummate Business CombinationViveon Health Acquisition Corp. announced the approval to extend the deadline for completing its business combination with Suneva Medical, Inc. until June 28, 2022, with additional monthly extensions possible up to December 28, 2022. This extension aims to provide adequate time for finalizing the merger, which involves filing a registration statement with the SEC. The extension was approved by Viveon Health's stockholders during its Annual Meeting on March 18, 2022.BioSpaceSuneva Medical Appoints Michael Brower as Chief Financial OfficerSuneva Medical appointed Michael Brower as Chief Financial Officer, effective February 28. Brower brings over 25 years of financial leadership, including roles at Vivatia Skin Care and Soyka Health. He will lead fundraising and partnership development as Suneva pursues its SPAC merger with Viveon Health.